ALSO NOTED: Anemia drugs back in the spotlight; Biodel completes VIAject enrollment; and much more...

> The FDA has revealed two new studies that show cancer patients may be more likely to die while using Amgen's blockbuster drugs Aranesp and Epogen (also sold under the brand name Procrit by Johnson & Johnson). Report

> Biodel has completed enrollment of its two Phase III clinical trials of VIAject, an injectable meal-time insulin for use by patients with Type 1 and Type 2 diabetes. Release

> Chutes & Ladders: Pharmos has made a number of changes to its board of directors and management. Release

> Chutes & Ladders: ViroPharma has appointed Thomas F. Doyle as vice president, strategic initiatives. J. Peter Wolf has been promoted to vice president, general counsel and secretary of the Board of Directors. Release

> So far, personalized medicine isn't perfectly personalized. New data shows that diagnostic tests to determine whether women should take certain breast cancer drugs have a failure rate of up to one-quarter. Report

> At a Morgan Stanley pharma conference yesterday, Schering-Plough CEO Fred Hassan was quizzed and requizzed by investors about the Vytorin-Zetia controversy. Report

> It's increasingly apparent that some of our most-lauded new oncology agents carry pretty serious baggage: they can cause heart attacks. Report

And Finally... The pharmaceutical industry spends twice as much on marketing and promotion of drugs as it does on R&D. Report

Suggested Articles

AstraZeneca is picking up a delayed preclinical fibrosis candidate from RedX in a deal that gives the U.K. biotech a much needed cash boost.

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.